Umoja Biopharma, Inc.

Venture capital fundraising data show that $100m-plus mega-rounds continue to account for the vast majority of biopharmaceutical company VC financings, with overall investment in large rounds and indi

September ended and October began with an explosion of new venture capital available for biotech companies, raising expectations for VC fundraising by drug developers through the rest of 2024, especia

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Boehringer Ingelheim GmbH is closely

With multiple autologous CAR-T cell therapies approved and showing high levels of clinical activity against leukemias, lymphomas and multiple myeloma, an increasingly important arena of competition no